NewAmsterdam Pharma Company N.V. and Menarini Group have secured European marketing authorisations for Ubeslo and Evlarco, turning obicetrapib into a commercial-stage cholesterol therapy while leaving PREVAIL to answer the more consequential question of whether its LDL reductions translate into fewer cardiovascular events.
uniQure reports four-year ifezuntirgene data showing slower Huntington’s disease progression as its gene therapy BLA moves through FDA review.
Novo Nordisk licenses Hengrui’s once-weekly oral GLP-1/GIP candidate HRS-1596 in a deal worth up to $2.6 billion.
ALX Oncology’s evorpacept raises response to 63.6% in a HER2-retained, CD47-high gastric cancer subgroup, supporting biomarker-led development.
FDA approves Teva’s DEGEVMA as an Xgeva biosimilar across oncology bone-disease indications, expanding its U.S. denosumab portfolio.
Five-year CARTITUDE-2 data show 50% of 20 early-line relapsed multiple myeloma patients remained alive and progression-free after a single Carvykti infusion without maintenance therapy, strengthening the case for using CAR-T before heavily pretreated disease.
MediciNova has completed the final patient visit in the blinded portion of its 234-patient COMBAT-ALS study, starting the countdown to pivotal MN-166 results expected by year-end as MNOV shares emerge as one of September’s strongest-performing healthcare stocks.
Bio-Techne shareholders have approved Merck KGaA’s $11.3 billion cash acquisition, clearing a major hurdle in a transaction designed to expand the German group across multi-omics, spatial biology, precision diagnostics and cell therapy workflows.
FDA grants Priority Review to lower-dose Joenja for children with APDS weighing 13–27 kg, setting a January 30, 2027 decision date.
CARVYKTI keeps half of CARTITUDE-2 patients progression-free and treatment-free at five years after one infusion. See what the data mean.